Compare Gilead Sciences, Inc. (GILD) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Hormel Foods Corp — how do they compare? Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B), while Hormel Foods Corp trades at $19.44 (market cap $10.69B). The key difference: Gilead Sciences, Inc. is far larger — about 17.1× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Hormel Foods Corp for 99 Days on average.
| GILD | HRL | |
|---|---|---|
Market Cap | $182.40B | $10.69B |
Volume | 4,469,821 | 10,041,387 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $26.50 |
52-Week Low | $116.74 | $19.42 |
Typical Hold Time | 111 Days | 99 Days |
Enterprise Value | $205.46B | $12.67B |
Dividend Yield | 2.23% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Hormel Foods (HRL) trades at $19.55, down 1.66% on the day, with a bearish technical signal from moving averages. The company reported a net income margin of 2.82% for 2025, with recent quarterly EPS beats but a year-over-year decline in net income. Its acquisition of Brakebush for $1.06 billion aims to expand its foodservice chicken business, while the dividend yield remains a key attraction as a Dividend King.
The stock presents a mixed outlook: analyst consensus targets $24.25 imply upside, but high P/E of 31.53 and shrinking profit margins pose valuation and growth concerns. Risks include execution on acquisitions and consumer spending pressures, yet the strong dividend history offers income stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
